The #AMRconference is a platform for SMEs, start-ups, big pharma, academia, investors and public institutions to discuss strategies and specific challenges faced by the innovation ecosystem in bringing new antimicrobial treatments and diagnostics to the market.

The conference is the one-stop shop to catch up with the latest trends in the development of AMR products, by covering scientific, regulatory, financial and policy topics. Besides high-level talks, the conference is a great place to network and exchange views on innovative technologies, development paths and alternative business models with your peers. The conference also offers a one-to-one partnering to facilitate interactions.

Once more, the 8^th edition covered the whole innovation value chain, including scientific breakthrough, preclinical and clinical development, but also financial topics such as public funding for R&D, market incentive and investors’ perspective. Specific sessions were also dedicated to phage therapy, diagnostics, antifungals and anti-tuberculosis drug combinations. There was a special focus on One Health and on how artificial intelligence can foster prevention and smart use of antibiotics. Among other highlights were a start-up pitch, hosted by the pharma-backed incubator INCATE, and a presentation of scientific posters.